Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CG Oncology, Inc. - Common stock (NQ: CGON )

32.34 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 Next >
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
A Closer Look at 9 Analyst Recommendations For CG Oncology
Via Benzinga
Decoding 10 Analyst Evaluations For CG Oncology
Via Benzinga
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
- First Patient Dosed in Expanded Access Program and Enrollment Ongoing - 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
From CG Oncology Inc.
Via GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study 
From CG Oncology Inc.
Via GlobeNewswire
CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
CGON stock results show that CG Oncology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
Via Benzinga
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC - 
From CG Oncology Inc.
Via GlobeNewswire
IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline?
A bulging pipeline of IPOs are registered, ready to go, and closely watching Reddit's performance. Here are the concerns. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - 
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
The market's excited for these stocks, but there's no rush to buy them. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
3 attractive stocks that insiders are buying
The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all. 
Via MarketBeat
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Exposures US Equities
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology, Inc.
Via Business Wire
KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.